ConductScience.org, home

Paper33485437

South Africa responds to new SARS-CoV-2 variant.

Makoni M. Lancet, 2021. Cited by 50 papers, by iCite.

Cite this record

ConductScience Library. South Africa responds to new SARS-CoV-2 variant. Papers, record 33485437. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33485437

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
South Africa responds to new SARS-CoV-2 variant.
PubMed
Journal
Lancet
PubMed
Year
2021
PubMed
Publication types
News
PubMed
Citations, by iCite
50
iCite
Relative citation ratio, by iCite
2.16
iCite
Revised in PubMed
2021-02-01
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Makoni MMunyaradzi

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
COVID-19Major topic
Genetic VariationMajor topic
SARS-CoV-2Major topic
COVID-19 Vaccines
Disease Transmission, Infectious
Humans
South Africa

Source PubMed

Download CSV of topics

Cited by44

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.

PMIDTitleJournalYearIn PapersSource
42074269Advances in Ozone-Based Inactivation of SARS-CoV-2: An Updated Review.Int J Mol Sci2026https://conductscience.org/library/papers/42074269PubMed
39847599Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques.PLoS Pathog2025https://conductscience.org/library/papers/39847599PubMed
38746751Genomic surveillance and serological profile of SARS-CoV-2 variants circulating in Macaé and nearby cities, southeastern Brazil.Front Microbiol2024https://conductscience.org/library/papers/38746751PubMed
38472991Advances and Challenges in SARS-CoV-2 Detection: A Review of Molecular and Serological Technologies.Diagnostics (Basel)2024https://conductscience.org/library/papers/38472991PubMed
38149245Inducing enhanced neutralizing antibodies against broad SARS-CoV-2 variants through glycan-shielding multiple non-neutralizing epitopes of RBD.Front Immunol2023https://conductscience.org/library/papers/38149245PubMed
37708230From past to present: Exploring COVID-19 in Qatar's hemodialysis population across Omicron dominant and pre-Omicron periods.PLoS One2023https://conductscience.org/library/papers/37708230PubMed
37333517Multi-scale risk assessment and mitigations comparison for COVID-19 in urban public transport: A combined field measurement and modeling approach.Build Environ2023https://conductscience.org/library/papers/37333517PubMed
37275136Development of a universal real-time RT-PCR assay for detection of pan-SARS-coronaviruses with an RNA-based internal control.Front Microbiol2023https://conductscience.org/library/papers/37275136PubMed
37193986Clinical and laboratory features of SARS-CoV-2 variants across multiple rounds of pandemic waves in hospitalized children in an Iranian referral hospital.BMC Pediatr2023https://conductscience.org/library/papers/37193986PubMed
37015915Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants.Cell Discov2023https://conductscience.org/library/papers/37015915PubMed
36908419Modeling the positive testing rate of COVID-19 in South Africa using a semi-parametric smoother for binomial data.Front Public Health2023https://conductscience.org/library/papers/36908419PubMed
36534127The immunogenetics of COVID-19.Immunogenetics2023https://conductscience.org/library/papers/36534127PubMed
36298564The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection.Vaccines (Basel)2022https://conductscience.org/library/papers/36298564PubMed
36256664Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.PLoS One2022https://conductscience.org/library/papers/36256664PubMed
36116149Bioinformatics pipeline unveils genetic variability to synthetic vaccine design for Indian SARS-CoV-2 genomes.Int Immunopharmacol2022https://conductscience.org/library/papers/36116149PubMed
36097349The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity.J Med Virol2023https://conductscience.org/library/papers/36097349PubMed
36016342Disinfectants against SARS-CoV-2: A Review.Viruses2022https://conductscience.org/library/papers/36016342PubMed
35655960Evolutionary Traits and Genomic Surveillance of SARS-CoV-2 in South America.Glob Health Epidemiol Genom2022https://conductscience.org/library/papers/35655960PubMed
35501267Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures.J Microbiol Immunol Infect2022https://conductscience.org/library/papers/35501267PubMed
35419205Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution.Evol Med Public Health2022https://conductscience.org/library/papers/35419205PubMed

See all 44 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33485437

GET https://conductscience.org/api/papers/v1/33485437/cited_by?page=2